Hotchkis & Wiley Capital Management LLC Has $138.52 Million Holdings in Solventum Corporation $SOLV

Key Points

• Hotchkis & Wiley Capital Management LLC reduced its stake in Solventum Corporation (NYSE:SOLV) by 1.6% in the 1st quarter, now owning approximately 1.05% of the company, valued at $138.5 million.
• Several analysts have upgraded Solventum's stock ratings and price targets, with Morgan Stanley raising their objective to $103.00 and Wells Fargo increasing theirs to $79.00.
• Solventum reported strong earnings with $1.69 earnings per share for the quarter, exceeding estimates and setting a fiscal year 2025 guidance of 5.800-5.950 EPS.

Hotchkis & Wiley Capital Management LLC cut its position in Solventum Corporation (NYSE:SOLV - Free Report) by 1.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,821,606 shares of the company's stock after selling 29,374 shares during the quarter. Hotchkis & Wiley Capital Management LLC owned 1.05% of Solventum worth $138,515,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of SOLV. Rossby Financial LCC bought a new position in shares of Solventum during the first quarter worth about $25,000. Strengthening Families & Communities LLC raised its position in shares of Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock worth $25,000 after acquiring an additional 260 shares during the last quarter. Clarity Asset Management Inc. bought a new position in shares of Solventum during the fourth quarter worth about $25,000. Raiffeisen Bank International AG bought a new position in shares of Solventum during the fourth quarter worth about $29,000. Finally, Hara Capital LLC bought a new position in shares of Solventum during the first quarter worth about $38,000.

Solventum Trading Up 0.0%

NYSE SOLV traded up $0.02 during trading hours on Wednesday, hitting $72.94. 868,414 shares of the company's stock were exchanged, compared to its average volume of 1,082,888. The stock has a 50-day simple moving average of $73.76 and a 200 day simple moving average of $72.84. Solventum Corporation has a 1-year low of $59.35 and a 1-year high of $85.92. The firm has a market cap of $12.65 billion, a price-to-earnings ratio of 33.77, a PEG ratio of 1.76 and a beta of 0.52. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business had revenue of $2.16 billion during the quarter, compared to analysts' expectations of $2.12 billion. During the same quarter last year, the firm posted $1.56 earnings per share. The firm's revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities analysts forecast that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SOLV. Wall Street Zen downgraded Solventum from a "strong-buy" rating to a "buy" rating in a research report on Sunday. Argus upgraded Solventum from a "hold" rating to a "buy" rating and set a $90.00 price objective for the company in a research report on Tuesday, July 1st. Piper Sandler restated an "overweight" rating and set a $94.00 price objective (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Wells Fargo & Company raised their price objective on Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Solventum currently has a consensus rating of "Hold" and an average price target of $85.75.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.